Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.8 USD | +1.05% | +5.40% | -8.51% |
May. 06 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Financials (USD)
Sales 2021 | 172M | Sales 2022 | 317M | Capitalization | 380M |
---|---|---|---|---|---|
Net income 2021 | -8M | Net income 2022 | 35M | EV / Sales 2021 | 3.44 x |
Net cash position 2021 | 67.84M | Net Debt 2022 | 10.19M | EV / Sales 2022 | 1.23 x |
P/E ratio 2021 |
-77
x | P/E ratio 2022 |
10.7
x | Employees | 134 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 65.14% |
Latest transcript on Eagle Pharmaceuticals, Inc.
1 day | +3.04% | ||
1 week | +1.93% | ||
Current month | +16.14% | ||
1 month | +1.28% | ||
3 months | -20.44% | ||
6 months | -45.02% | ||
Current year | -9.18% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Graves
CEO | Chief Executive Officer | 61 | 13-10-31 |
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 07-02-28 |
Ryan Debski
CMP | Compliance Officer | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven B. Ratoff
DFI | Director of Finance/CFO | 81 | 07-02-28 |
Jennifer Simpson
BRD | Director/Board Member | 55 | 19-08-27 |
Richard Edlin
BRD | Director/Board Member | 63 | 17-03-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.54% | 28 M€ | -0.39% | ||
0.25% | 25 M€ | -1.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 4.785 | +0.74% | 50 672 |
24-05-16 | 4.75 | +3.04% | 125,668 |
24-05-15 | 4.61 | -1.28% | 56,288 |
24-05-14 | 4.67 | +3.78% | 62,535 |
24-05-13 | 4.5 | -0.88% | 246,295 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-9.18% | 61.69M | |
+10.23% | 9.11B | |
-10.76% | 5.21B | |
+53.60% | 4.83B | |
+7.56% | 4.09B | |
-21.42% | 2.35B | |
+14.68% | 2.32B | |
+25.03% | 2.27B | |
-30.36% | 2.19B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- EGRX Stock